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Abstract
 
Experimental autoimmune encephalomyelitis (EAE) is a CD4
 
1
 
 T lymphocyte–mediated dis-
ease of the central nervous system (CNS) characterized by mononuclear cell infiltration, demy-
elination, and paralysis. We previously demonstrated a role for chemokines in acute and relaps-
ing EAE pathogenesis. Presently, we investigated the role of CC chemokine receptor 2
(CCR2) in acute EAE. CCR2
 
2
 
/
 
2
 
 mice did not develop clinical EAE or CNS histopathology,
and showed a significant reduction in T cell– and CNS-infiltrating CD45
 
high
 
F4/80
 
1
 
 monocyte
subpopulations. Peripheral lymphocytes from CCR2
 
2
 
/
 
2
 
 mice produced comparable levels of
interferon-gamma (IFN-
 
g
 
) and interleukin (IL)-2 in response to antigen-specific restimulation
when compared with control mice. Adoptively transferred myelin oligodendrocyte glycopro-
tein 35-55–specific T cells lacking expression of CCR2 were able to induce EAE, whereas
CCR2
 
2
 
/
 
2
 
 recipients of wild-type T cells failed to develop disease. These results suggest that
CCR2 expression on host-derived mononuclear cells is critical for disease induction.
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Introduction
 
Experimental autoimmune encephalomyelitis (EAE) is a
CD4
 
1
 
 T cell–mediated demyelinating disease of the central
nervous system (CNS) that serves as a model for multiple
sclerosis (MS) (1). The pathogenic mechanisms of disease
development include antigen-specific T cell activation and
Th1 differentiation (2) followed by T cell (3) and mac-
rophage migration into CNS with little or no polymorpho-
nuclear cell infiltration (4). The mechanism by which cells
traffic to the CNS and accumulate before and during clini-
cal disease is not well understood. However, entry of acti-
vated T cells into tissue compartments is a process gov-
erned by integrins (5–7).
 
An additional essential step during pathogenesis of tissue
specific inflammatory diseases is chemokine-induced re-
cruitment and/or accumulation of leukocytes within tissue
sites. Chemokines are potent leukocyte chemoattractants
that can be divided into four highly conserved families: the
 
C-x-C, C-C, C, and C-x
 
3
 
-C families, based on the position
of the first two cysteines in the NH
 
2
 
 terminus (8). CC
chemokine family members have been implicated as func-
tional mediators of immunopathology in EAE (reviewed in
reference 9) and are ligands for seven transmembrane-span-
ning receptors that induce signaling through a G-protein–
linked pathway resulting in cytoskeletal rearrangement, in-
tracellular calcium increases, adhesion to endothelium or
extracellular matrix proteins, Th1/Th2 differentiation, costim-
ulation, IL-2 production, proliferation, and chemotaxis (10).
Our previous observations showing differential expres-
sion and function of CC chemokines in development of
EAE (11) led us to hypothesize that infiltrating mononu-
clear cells require CC chemokine receptor (CCR) expres-
sion corresponding to the chemokine ligands produced
during disease pathogenesis in order for mononuclear cells
to accumulate in the CNS and induce subsequent disease.
In this study, we investigated the role of CCR2 during in-
duction of acute EAE in an effort to understand mononu-
clear cell migration and/or accumulation during the devel-
opment of EAE.
 
Materials and Methods
 
Animals.
 
Control female B6129PF2/J and C57BL/6 mice
were purchased from The Jackson Laboratory. CCR2
 
2
 
/
 
2
 
 mice
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were on an outbred C57BL/6J 
 
3
 
 129/Ola genetic background
(12). Mice were born and bred under specific pathogen-free con-
ditions and subsequently maintained at Northwestern University.
Heterozygous CCR2
 
1
 
/
 
2
 
5
 
1
 
/
 
2
 
 littermate controls were generated
by crossing the CCR2
 
2
 
/
 
2
 
 and CCR5
 
2
 
/
 
2
 
 (12) homozygote mice.
C57BL/6J mice were subsequently used as wild-type controls for
the CCR2
 
2
 
/
 
2
 
 mice as there were no differences between the
CCR2
 
1
 
/
 
2
 
5
 
1
 
/
 
2
 
 heterozygous control mice, B6129PF2/J, or
C57BL/6J mice. Animal care and use was performed in accor-
dance with Northwestern University and National Institutes of
Health guidelines.
 
Antigens, Abs, and Flow Cytometry.
 
Myelin oligodendrocyte
glycoprotein (MOG)35–55 (MEVGWYRSPFSRVVHLYRNGK)
was purchased from Peptides International, amino acid com-
position was verified by mass spectrometry, and purity was
 
.
 
98%. mAbs to CD4 (RM4-5), CD8a (Ly-2), CD19 (1D3),
CD45 (Ly-5), purified Fc Block (2.4G2), F4/80, and isotype
control Abs were obtained commercially (BD PharMingen and
Caltag Laboratories). CNS mononuclear cells were isolated by
centrifugation (500 
 
g
 
) at 24
 
8
 
C from the interface of a 30–70%
discontinuous Percoll (Amersham Pharmacia Biotech) gradient
and 10
 
6
 
 cells were preincubated with Fc Block for 15 min at
4
 
8
 
C in PBS containing 0.1% NaN
 
3
 
 and 2% BSA (Sigma-
Aldrich), followed by specific and isotype control Ab staining.
Data collection and analysis were performed on a FACSCali-
bur™ flow cytometer using CELLQuest™ software (Becton
Dickinson).
 
Cell Culture.
 
Lymphocytes were cultured in DMEM (GIBCO
BRL) as described previously (13). Adoptive transfer cells were
cultured at 10
 
6
 
 cells/ml in DMEM for 72 h with 30 
 
m
 
g/ml
MOG35–55, 20 ng/ml rmIL-12 (R&D Systems), and 
 
g
 
-irradi-
ated (3000 rad) splenocytes (5 
 
3
 
 10
 
6
 
 cells/ml).
 
Disease Induction and Clinical Evaluation.
 
For actively induced
EAE, mice were immunized with 200 
 
m
 
g of MOG35–55 emulsi-
fied
 
 
 
in CFA containing 4 mg/ml 
 
Mycobacterium tuberculosis
 
 (Difco)
subcutaneously and given 200 ng of pertussis toxin (List Biologi-
cal Laboratories) intravenously on the day of and 2 d after immu-
nization. For adoptively induced EAE, donor wild-type and
CCR2
 
2
 
/
 
2
 
 mice were immunized with MOG35–55 in CFA. 10 d
after immunization, draining LNs were harvested and cultured as
described above. 5 
 
3
 
 10
 
6
 
 CD4
 
1
 
 T cells transferred intravenously
to recipients who received 100 ng of pertussis toxin intravenously
on the day of and 2 d after cell transfer. Individual animals were
graded according to clinical severity as follows: grade 0, no ab-
normality; grade 1, limp tail; grade 2, limp tail and hind limb
weakness; grade 3, partial hind limb paralysis; grade 4, complete
hind limb paralysis.
 
CNS Chemokine and CCR Reverse Transcriptase–PCR.
 
Total
RNA was isolated from spinal cords using TRIzol reagent
(GIBCO BRL), DNase treated (Promega), and converted to
cDNA (CLONTECH Laboratories, Inc.). Chemokine reverse
transcriptase (RT)–PCR was performed as described previously
(14). PCR conditions were: 94
 
8
 
C for 3 min, followed by 40 cy-
cles of 30 sec at 94
 
8
 
C, 30 sec at 60
 
8
 
C, and 1 min 30 sec at 72
 
8
 
C,
with a final extension at 72
 
8
 
C for 3 min. CCR primer sequences
used include: CCR1, (15); CCR2, sense 5
 
9
 
-GGTCATGATC-
CCTATGTGG-3
 
9
 
, antisense 5
 
9
 
-CTGGGCACCTGATTTAA-
AGG-3
 
9
 
; CCR5 sense 5
 
9
 
-GCTGAAGAGCGTGACTGATA-3
 
9
 
,
antisense 5
 
9
 
-GAGGACTGCATGTATAATGA-3
 
9
 
; CCR7 sense
5
 
9
 
-ACAGCGGCCTCCAGAAGAACAGCGG-3
 
9
 
, antisense
5
 
9
 
-TGACGTCATAGGCAATGTTGAGCTG-3
 
9
 
. PCR prod-
ucts were visualized by ethidium bromide 2% agarose gel electro-
phoresis.
 
Cytokine and Chemokine ELISA.
 
Assessment of cytokine pro-
duction was determined from LN culture supernatants harvested
after a 48-h stimulation with MOG35–55 peptide as described
previously (13). Assessment of chemokine expression was per-
formed from tissue samples using described previously noncom-
mercial ELISAs (11).
 
Statistical Analysis.
 
Comparisons of disease incidence were
analyzed by the X
 
2
 
 analysis, using Fisher’s exact probability test.
Statistical significance of cytokine levels, disease onset, and disease
severity was analyzed using the Student’s 
 
t
 
 test for comparisons of
two means. Values of
 
 P 
 
#
 
 0.05 were considered significant.
 
Results and Discussion
 
Chemokine Expression in the Spinal Cord during Acute EAE.
 
To understand the role for chemokine receptors in EAE
pathogenesis, we first examined the CNS for chemokine
receptor and ligand mRNA expression by RT–PCR in-
cluding monocyte chemotactic protein-1 (CCL2), mac-
rophage inflammatory protein-1
 
a
 
 (CCL3), macrophage in-
flammatory protein-1
 
b
 
 (CCL4), RANTES (CCL5 [16]),
CCR1, CCR2, CCR5, and CCR7. Spinal cords from
three different time points corresponding to preclinical
when no animals were exhibiting disease symptoms, disease
onset when animals showed first symptoms of EAE, and
peak EAE were evaluated. The results shown in Fig. 1 A
demonstrate CCL2, CCL4, and CCL5 CNS chemokine
mRNA expression in wild-type CNS at all three time
points examined. CCL3 expression was not detected until
clinical onset of disease and remained expressed through
acute clinical disease. The results shown in Fig. 1 A also
demonstrate CCR2 and 5 mRNA expression at all three
time points measured. Unlike CCR2 and 5 expression,
CCR1 and 7 expression was not detected until peak
acute EAE.
CNS CCL2 protein production during acute EAE was
also examined based on its known role in other EAE sus-
ceptible mouse strains (11) and its role as a ligand for
CCR2 (17). The results shown in Fig. 1 B demonstrate
low levels of CNS CCL2 and CCL5 in preclinical mice. As
disease progresses though initial clinical symptoms to peak
acute disease, levels of CCL2 and CCL5 increase dramati-
cally. CCL3 protein expression was lower compared with
CCL2 and CCL5 levels and did not correlate with increas-
ing disease severity (Fig. 1 B). There was no CCL4 protein
detected in any spinal cords examined (data not shown).
Taken together, these data demonstrate the CNS presence
of both CCR2 and its ligand, CCL2, during EAE develop-
ment.
 
CCR2
 
2
 
/
 
2
 
 Mice Are Protected from Developing Clinical EAE.
 
To determine if CCR2 was required for acute EAE, we
used CCR2
 
2
 
/
 
2
 
 mice for active disease induction.
B6129PF2, C57BL/6, CCR2
 
1
 
/
 
2
 
5
 
1
 
/
 
2
 
 (control groups),
and CCR2
 
2
 
/
 
2
 
 mice were induced to develop active EAE
and monitored for the development of clinical disease. The
results shown in Fig. 2 demonstrate that control mice de-
veloped typical disease whereas CCR2
 
2
 
/
 
2
 
 mice showed a
significant reduction (
 
P
 
 , 
 
0.001) in acute EAE, with only 
901
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one mouse showing very mild disease. Spinal cord sections
from controls showed extensive meningial, perivascular, and
parenchymal infiltrates, whereas sections from CCR2
 
2
 
/
 
2
 
mice showed no mononuclear cell infiltration (data not
shown).
 
Flow Cytometric Analysis of CNS-infiltrating Cells.
 
To
discern any differences in infiltrating cell composition we
performed flow cytometric analysis on CNS mononuclear
cells. Spinal cord mononuclear cells were isolated from
representative mice when control groups reached peak
acute clinical disease. The immunophenotyping results are
shown in Table I and reveal that control mouse spinal cord
infiltrate was composed of T cells (CD4
 
1
 
 and CD8
 
1
 
) and
F4/80
 
1
 
 cells. Not only was there a decrease in the total
number of CNS mononuclear cells in the CCR2
 
2
 
/
 
2
 
 spinal
cords, but there was also a decrease in the percentage of in-
filtrating T cells (
 
,
 
0.1%). Differential CD45 staining in-
 
tensity coupled with F4/80 staining has been used to dis-
tinguish between infiltrating macrophages and resident
microglia. Infiltrating macrophages are CD45
 
high
 
F4/80
 
1
 
,
while resident microglial cells are CD45
 
low
 
F4/80
 
1
 
 (18).
Our results indicated that most of the total CNS mononu-
clear cells from the spinal cords of CCR2
 
2
 
/
 
2
 
 mice were
resident microglial cells, not infiltrating macrophages. In
contrast, 
 
z
 
50% of the total CNS mononuclear cells from
the control mice were CD45 bright, corresponding to in-
filtrating macrophages.
 
Peripheral Antigen Recall Immune Responses.
 
Disease pro-
tection in CCR2
 
2
 
/
 
2
 
 mice could result from a defect in
IFN-
 
g
 
 responses as described previously (19). When con-
trols were showing peak clinical EAE, representative ani-
mals were killed and draining LN cells and splenocytes
were stimulated in vitro with MOG35–55 to determine
their ability to produce cytokines. The results in Fig. 3 in-
dicate that there was no defect in CCR2
 
2/2 cells from
draining LNs (A and B) or spleen (C and D) to produce
IFN-g or IL-2 compared with control groups. In addition
to producing proinflammatory cytokines, CCR22/2 T cells
showed MOG35–55 dose-dependent proliferation re-
sponses and no IL-4 expression when compared with all
controls (data not shown).
CCR22/2 Adoptive Transfer Recipients Do Not Develop
Clinical EAE. To help understand disease protection in
CCR22/2 mice we performed adoptive transfer EAE stud-
ies. The rationale behind this approach was to determine if
CCR2 expression was necessary on disease-inducing
CD41 T cells or whether host-derived infiltrating T cells
and/or monocytes required CCR2 expression for disease
Figure 1. CNS chemokine and chemokine receptor expression. (A)
CCL2, CCL4, CCL5, and chemokine receptor mRNA was detected in
CNS tissue samples using RT–PCR at all three time points examined af-
ter EAE induction. (B) CNS chemokine protein expression for CCL2,
CCL3, CCL4, and CCL5 was quantitated from tissue samples using spe-
cific ELISA. The results from two representative mice from each time
point are shown. In all cases the data shown are representative of two in-
dependent experiments.
Figure 2. CCR2-deficient mice do not develop clinical EAE. Mice
were monitored for development of clinical disease. The data are ex-
pressed as the mean clinical disease score for all mice in each group as a
function of days after immunization with disease incidence indicated in
parentheses. Both mean clinical disease severity and disease incidence
were significantly decreased in CCR22/2 animals relative to C57BL/6,
B6129PF2, and CCR21/251/2 controls (P , 0.001) over the entire
course of the experiment. The data shown are representative of four inde-
pendent experiments.902 CCR2 and Induction of EAE
development. Sorted, antigen-restimulated CD41 T cells
from wild-type donors were transferred intravenously to
either wild-type or CCR22/2 recipients, and sorted, anti-
gen-restimulated CD41 T cells from CCR22/2 donors
were transferred intravenously to either wild-type or
CCR22/2 recipients. The results of this experiment shown
in Fig. 4 demonstrate that wild-type recipients of wild-type
MOG-specific CD41 T cells developed acute EAE
whereas wild-type recipients of MOG-specific CD41 T
cells from CCR22/2 donors developed a significantly less
severe acute EAE (P , 0.05). In contrast, CCR22/2 recip-
ient mice, regardless of whether they received MOG-spe-
cific CD41 T cells from wild-type or CCR22/2 donors,
failed to develop EAE. These results suggest that encepha-
litogenic T cell expression of CCR2 is not a critical factor
in development of EAE; rather, expression on host-derived
cells is critical for disease induction.
CNS Mononuclear Cell Infiltration in Adoptive Transfer Re-
cipients. To determine the mechanism of disease inhibi-
tion seen in CCR22/2 recipients of either wild-type or
CCR22/2 CD41 T cells (Fig. 4), we examined CNS infil-
trating mononuclear cells by flow cytometry. When wild-
type recipients of wild-type CD41 T cells showed peak
clinical disease, the immunophenotype of the CNS infil-
trating cells for all groups was determined. The results
shown in Table I demonstrate that spinal cord infiltrates
from wild-type recipients of wild-type MOG-specific
CD41 T cells were composed of T cells, few B cells,
CD45highF4/801 monocytes, and CD45lowF4/801 micro-
glial cells. Spinal cord infiltrates from wild-type recipients
of CCR22/2 MOG-specific CD41 T cells exhibited a sim-
ilar cellular composition. Both of these groups developed
Table I. Decreased Recruitment/Accumulation of T Cells and Infiltrating Monocytes in CCR22/2 Mice
F4/80
Disease* Cell recovery‡ CD4 CD8 CD19 CD45high CD45low
Experiment 1§
C57BL/6 Yes 1.6 3 105 20 8 ,15 4 2 0
B6129PF2 Yes 1.7 3 105 26 9 ,14 8 1 9
CCR22/2 No 1.1 3 104 ,1 ,1 ,118 5
Experiment 2i
Donor ® recipient mice
C57BL/6 CD41 T cells ® C57BL/6 Yes 9.5 3 104 15 11 1 20 55
C57BL/6 CD41 T cells ® CCR22/2 No 2.8 3 104 4 1 22 4 59
CCR22/2 CD41 T cells ® C57BL/6  Yes 9.5 3 104 11 13 3 11 59
CCR22/2 CD41 T cells ® CCR22/2 No 1.8 3 104 4 2 20 5 62
*Refer to Figs. 1 and 4 for development of clinical disease.
‡Average number of mononuclear cells recovered per spinal cord.
§Experiment 1. Characterization of CNS mononuclear cell infiltration during active EAE by flow cytometric analysis. The data shown are represen-
tative of three independent experiments. The data represent cell percentages determined by forward versus side and CD45 gating.
iExperiment 2. Characterization of CNS mononuclear cell infiltration during adoptive EAE by flow cytometric analysis. The data shown are repre-
sentative of two independent experiments. The data represent cell percentages determined by forward versus side and CD45 gating.
Figure 3. Lymphocytes from CCR22/2 mice produce proinflamma-
tory cytokines upon antigen restimulation. B6129PF2, C57BL/6, and
CCR22/2 mice were monitored for the development of clinical EAE. At
the time B6129PF2 mice showed peak acute clinical disease, draining LN
(A and B) and splenic cells (C and D) pooled from six representative mice
for each group were restimulated with the immunizing peptide in vitro.
Cultured supernatant was harvested at 48 h and measured for the produc-
tion of IL-2 and IFN-g by specific ELISA. CCR22/2 lymphocytes pro-
duced comparable levels of IFN-g and IL-2 to control C57BL/6 lym-
phocytes in response to specific peptide challenge. The data shown are
representative of three independent experiments.903 Fife et al. Brief Definitive Report
EAE (Fig. 4). There was a dramatic reduction in the pres-
ence of both CD41 and CD81 T cells and CD45highF4/801
monocytes in both CCR22/2 recipient groups regardless of
whether they received MOG-specific CD41 T cells from
CCR22/2 or wild-type donors (Table I). Both of these
CCR22/2 recipient groups also failed to develop EAE. In-
terestingly, in the absence of a large T cell and monocyte
infiltrate in the CCR22/2 recipients, the percentage of
CD191 B cells was dramatically increased. This is not an
absolute increase in B cells as can be seen by the dramatic
decrease in total cell recovery from the spinal cords of both
CCR22/2 recipient groups; rather, it is most likely a rela-
tive increase due to the decrease in the presence of both T
cells and monocytes. These results from this experiment
demonstrate that CCR22/2 recipient mice contain very
few CNS infiltrating mononuclear cells and that they are
resident microglial cells (CD45lowF4/801; Table I). For a
comparison, when the CNS of normal wild-type mice that
have never been immunized with MOG35–55 or never re-
ceived MOG35–55-specific T cells was analyzed for the
presence of mononuclear cells by flow cytometry, only
CD45lowF4/801 microglia were found (data not shown).
Collectively, these data demonstrate that CCR2 expression
is a critical factor for EAE induction by regulating the accu-
mulation of host-derived CNS mononuclear cells.
At least five distinct possibilities exist to potentially ex-
plain the current findings. (a) T cells from CCR22/2 mice
lack appropriate adhesion molecules known to be impor-
tant in initial migration from blood to CNS. We found that
VLA-4 (5) and CD44 (20) were expressed on activated T
cells in the CCR22/2 mice (data not shown) and therefore
considered this possibility unlikely. (b) There was an al-
tered Th1 phenotype in the CCR22/2 mice (19) which
contributed to the lack of disease induction. Our findings
indicated that CCR22/2 mice mounted a similar MOG35–
55-specific Th1 response as measured by IFN-g expression
compared with the control groups. (c) CCR2 expression
on T cells was required for disease development, presum-
ably by regulating migration to the CNS. To address this
possibility we performed adoptive transfer EAE induction
and demonstrated that wild-type recipients of MOG35–
55-specific CCR22/2 T cells developed EAE (Fig. 4) and
had significant numbers of T cells in the CNS when com-
pared with controls (Table I). Therefore, it does not appear
likely that CCR2 expression on MOG35–55-specific, dis-
ease-inducing T cells is necessary for EAE development.
(d) CCR2 expression is required on monocytes/macro-
phages for CNS migration and/or accumulation. We favor
this hypothesis based on our results demonstrating that
CCR22/2 recipients of MOG35–55-specific wild-type
CD41 T cells fail to develop EAE (Fig. 4) as well as fail to
show appreciable monocyte (CD45highF4/801) accumula-
tion in the CNS compared with the positive control (Table
I). From these results, however, we are unable to rule out
the possibility that CCR2 expression is required on host-
derived T cells for EAE development. We do not think
that host-derived T cells are required for EAE since disease
can be adoptively induced in SCID mice lacking bystander
T cells (21). (e) There was a deficiency in CNS microglia
and/or an inability of these cells to migrate within the CNS
during disease development. Similar numbers of microglia
(CD45lowF4/801) were found in wild-type and CCR22/2
mice, indicating that there is no deficiency in the numbers
of microglia (Table I). However, our results cannot rule
out the possibility that microglia in CCR22/2 mice have a
defect in their ability to migrate within the CNS and con-
tribute to EAE pathogenesis.
Several other inflammatory models have recently identi-
fied critical roles for CCR2 expression on a variety of cell
types, including monocytes. CCR22/2 mice have impaired
monocytic responses, including adhesion, trafficking, and
granuloma formation (22, 23). CCR22/2 mice were un-
able to clear infection by Listeria monocytogenes, suggesting a
defect in the macrophage-mediated clearance mechanism
(24). CCR2 was also shown to be important in a mouse
model of hyperreactive airway disease mediated through
MCP-1 (25). Furthermore, CCR2 mice have reduced ath-
erosclerosis due to a defect in monocyte migration (26).
Our present results lead us to postulate a model for
chemokines, especially CCL2, and its receptor, CCR2, in
pathogenesis of CNS autoimmune demyelinating disease.
Initial activated CD41 T cell CNS entry is mediated by in-
teractions of VLA-4 and VCAM-1, and perhaps constitu-
Figure 4. CCR22/2 recipients do not develop clinical EAE. Mice
were monitored for the development of clinical disease after the adoptive
transfer of MOG35–55-reactivated CD41 T cells. The data are expressed
as the mean clinical disease score for all mice in each group as a function
of days after adoptive transfer with disease incidence in parentheses. Both
mean clinical disease severity and disease incidence were significantly de-
creased in both CCR22/2 recipient groups compared with the C57BL/6
wild-type recipient group receiving CD41 T cells from wild-type
C57BL/6 donors by the Student’s t test and X2 analysis over the entire
course of the experiment. The C57BL/6 recipient mice receiving
CCR22/2 CD41 T cells was significantly reduced when compared with
the wild-type C57BL/6 to C57BL/6 recipient group at the days marked
(*; P , 0.05). The data shown are representative of two independent ex-
periments.904 CCR2 and Induction of EAE
tively expressed chemokines such as fractalkine (CX3CL1
[27]). Once lymphocytes are in the perivascular space, they
presumably recognize antigen presented by local APCs,
leading to increased chemokine and inflammatory cytokine
expression by T cells, and resulting in further induction of
chemokine expression by glial cells. Indeed, astrocytes have
been shown to express CCL2 and may participate in the
recruitment of CCR21 monocytes during disease develop-
ment (28). However, in the absence of CCR2 expression,
monocytes would fail to accumulate in the CNS in re-
sponse to CCL2 expression despite the presence of T cells
and sufficient numbers would not be present to serve as ad-
ditional sources of chemokines and/or end stage effector
cells involved in tissue damage, demyelination, and subse-
quent clinical disease. Our data demonstrate an important
role for specific chemokine receptor expression and in vivo
cellular recruitment during the EAE pathogenesis and open
the possibility of using CCR2 receptor antagonists for tis-
sue specific autoimmune disease therapy.
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